دورية أكاديمية
أعرض في EDS

Treatment with Janus kinase inhibitors in juvenile dermatomyositis: A review of the literature.

التفاصيل البيبلوغرافية
العنوان: Treatment with Janus kinase inhibitors in juvenile dermatomyositis: A review of the literature.
المؤلفون: Sener S; Hacettepe University Faculty of Medicine, Department of Pediatrics, Division of Pediatric Rheumatology, Ankara, Turkey., Cam V; Hacettepe University Faculty of Medicine, Department of Pediatrics, Division of Pediatric Rheumatology, Ankara, Turkey., Ozen S; Hacettepe University Faculty of Medicine, Department of Pediatrics, Division of Pediatric Rheumatology, Ankara, Turkey., Batu ED; Hacettepe University Faculty of Medicine, Department of Pediatrics, Division of Pediatric Rheumatology, Ankara, Turkey. Electronic address: ezgidenizbatu@yahoo.com.
المصدر: Seminars in arthritis and rheumatism [Semin Arthritis Rheum] 2024 Jun; Vol. 66, pp. 152426. Date of Electronic Publication: 2024 Mar 01.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: W.B. Saunders Country of Publication: United States NLM ID: 1306053 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-866X (Electronic) Linking ISSN: 00490172 NLM ISO Abbreviation: Semin Arthritis Rheum Subsets: MEDLINE
أسماء مطبوعة: Publication: Philadelphia Pa : W.B. Saunders
Original Publication: New York, Stratton.
مواضيع طبية MeSH: Dermatomyositis*/drug therapy , Janus Kinase Inhibitors*/therapeutic use , Pyrimidines*/therapeutic use, Humans ; Child ; Pyrazoles/therapeutic use ; Child, Preschool ; Adolescent ; Treatment Outcome ; Female ; Male ; Azetidines/therapeutic use ; Sulfonamides/therapeutic use ; Piperidines/therapeutic use ; Infant ; Nitriles/therapeutic use ; Purines
مستخلص: Background/objectives: Janus kinase (JAK) inhibitors have been increasingly used in the treatment of juvenile dermatomyositis (JDM). This review aims to comprehensively analyze previous studies concerning the utilization of JAK inhibitors in JDM patients.
Methods: We conducted a thorough review of MEDLINE and Scopus databases, spanning from their inception to September 1st, 2023, to identify articles involving JDM patients treated with JAK inhibitors.
Results: Our literature search yielded 26 articles that encompassed 195 patients with JDM who received JAK inhibitors. The median (min-max) age of the patients was 4.9 (1-17) years (F/M:1.2). The most frequently used JAK inhibitor was tofacitinib (57.4 %), and improvement was achieved in 89.7 % of patients treated with tofacitinib. The improvement rate for ruxolitinib, which was the second most frequently used JAK inhibitor (27.2 %), was 69.2 %. For baricitinib (15.4 %), the improvement rate was 92.7 %. The most prevalent indication for JAK inhibitor use was resistant/recurrent skin involvement (34.7 %) followed by resistant/recurrent muscle involvement (28.6 %). Adverse events were reported in 72.1 % of the patients; an increase in infections (especially upper respiratory tract infections) was the most common side effect.
Conclusion: Our findings suggest that JAK inhibitors may be a good therapeutic option, particularly in the management of refractory JDM cases with an acceptable safety profile. However, further controlled studies are essential to establish a higher level of evidence for the optimal use of JAK inhibitors in JDM treatment.
Competing Interests: Declaration of competing interest Ezgi Deniz Batu receives payment for speakers’ bureaus from Novartis. Seza Ozen receives consultancy fees and payment for speakers’ bureaus from Novartis and Sobi. Other authors did not declare any conflicts of interest.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
فهرسة مساهمة: Keywords: Janus kinase inhibitors; Juvenile dermatomyositis; Treatment
المشرفين على المادة: 0 (Janus Kinase Inhibitors)
0 (Pyrimidines)
0 (Pyrazoles)
87LA6FU830 (tofacitinib)
ISP4442I3Y (baricitinib)
82S8X8XX8H (ruxolitinib)
0 (Azetidines)
0 (Sulfonamides)
0 (Piperidines)
0 (Nitriles)
0 (Purines)
تواريخ الأحداث: Date Created: 20240305 Date Completed: 20240512 Latest Revision: 20240514
رمز التحديث: 20240514
DOI: 10.1016/j.semarthrit.2024.152426
PMID: 38442462
قاعدة البيانات: MEDLINE
الوصف
تدمد:1532-866X
DOI:10.1016/j.semarthrit.2024.152426